Results 171 to 180 of about 1,253,570 (258)

Efficacy and Safety of Once‐Weekly Semaglutide 2.0 mg as an Add‐On to Dose‐Reduced Insulin Glargine versus Dose‐Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE)

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9304-9316, October 2026.
ABSTRACT Aims Type 2 diabetes (T2D) management with basal insulin can lead to hypoglycaemia and weight gain. SUSTAIN OPTIMIZE compared once‐weekly semaglutide 2.0 mg as add‐on to dose‐reduced insulin glargine (Sema+IGlarreduced) versus dose‐titrated IGlar (IGlartitrated) on glycated haemoglobin (HbA1c), body weight (BW), daily insulin dose, and ...
Helena W. Rodbard, Concetta Irace, Jevitha Lobo, Konstantinos Makrilakis, Prachi Priyadarshini, Suvanjaa Sivalingam, Santiago Tofé Povedano, Anuj Bhargava   +7 more
wiley   +1 more source

GLP‐1 Receptor Agonists and Risk of Skin Cancer in Adults With Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9377-9384, October 2026.
ABSTRACT Aims Existing evidence regarding the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and risk of melanoma and non‐melanoma skin cancer (NMSC) is inconclusive. This study aimed to assess the association between GLP‐1RA initiation and risks of melanoma and NMSC versus sodium–glucose cotransporter 2 inhibitors (SGLT2is ...
Huilin Tang, Bingyu Zhang, Ying Lu, Ting Zhou, Yiwen Lu, César A. Briceño, Jiali Han, Yong Chen   +7 more
wiley   +1 more source

Sulfonylurea Receptor 1, Transient Receptor Potential Cation Channel Subfamily M Member 4, and KIR6.2:Role in Hemorrhagic Progression of Contusion. [PDF]

J Neurotrauma, 2019
Gerzanich V, Stokum JA, Ivanova S, Woo SK, Tsymbalyuk O, Sharma A, Akkentli F, Imran Z, Aarabi B, Sahuquillo J, Simard JM.   +10 more
europepmc   +1 more source

Association Between Time in Range and Advanced Cardiovascular‐Kidney‐Metabolic Syndrome in Older Adults With Type 2 Diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9265-9274, October 2026.
ABSTRACT Aims Cardiovascular, kidney and metabolic diseases are pathophysiologically interrelated and are conceptualised within the cardiovascular‐kidney‐metabolic (CKM) syndrome framework. However, evidence linking continuous glucose monitoring (CGM) to CKM syndrome remains limited.
Hang Su, Jiaying Ni, Jinghao Cai, Wei Zhu, Yufei Wang, Jian Zhou, Jingyi Lu, Xiaojing Ma   +7 more
wiley   +1 more source

Considering Deintensification and Deprescribing with Higher HbA1c Targets in Vulnerable Older Adults with Type 2 Diabetes: A Retrospective Database Study. [PDF]

Diabetes Ther
Koto R, Yoshida S, Nakajima A, Sugimoto K.   +3 more
europepmc   +1 more source

A New Highly Concentrated Insulin Aspart AT278 (500 U/mL) Demonstrates Ultra‐Rapid Pharmacokinetic and Pharmacodynamic Properties in Type 2 Diabetes Regardless of BMI

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9423-9432, October 2026.
ABSTRACT Aims To evaluate the pharmacokinetics, pharmacodynamics, and safety of a novel U500 insulin aspart formulation (AT278 [500 U/mL]; AT278‐U500) compared with standard concentration insulin aspart (InsAsp [100 U/mL]; InsAsp‐U100) and U500 human regular insulin (HumIns [500 IU/mL]; HumIns‐U500). Materials and Methods This single‐centre, randomised,
Eva Svehlikova, Christina Gatschelhofer, Bettina Lackner, Maria Ratzer, Gabriele Fluhr, Anja Stoisser, Gregor Kolaric, David Gerring, Sarah Howell, Jan Jezek, Fiona Lawrence, Thomas R. Pieber   +11 more
wiley   +1 more source

Glycemic and Renal Effects of SGLT2 Inhibitors in Monogenic Diabetes: A Real‐World National Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9633-9643, October 2026.
ABSTRACT Aims Evidence regarding the efficacy and safety of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in monogenic diabetes is limited. We evaluated real‐world metabolic, renal, and safety outcomes of SGLT2i therapy in adults with monogenic diabetes.
Estelle Audrain, Pierre Bel Lassen, Christine Bellanné‐Chantelot, Marie Christine Vantyghem, Hippolyte Dupuis, Tiphaine Vidal‐Trecan, Nicolas Chevalier, Danièle Dubois‐Laforgue, Sophie Lamothe, Camille Vatier, Orianne Villard, René Valéro, Claire Briet, Corinne Vigouroux, Cécile Ciangura, Chloé Amouyal   +15 more
wiley   +1 more source

Time to Insulin Initiation Among Patients With Type 2 Diabetes Treated With Second‐Line Antidiabetic Drugs

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9655-9667, October 2026.
ABSTRACT Objective To examine the effect of second‐line treatments (insulin secretagogues, thiazolidinediones, glucagon‐like peptide‐1 (GLP‐1) receptor agonists, dipeptidyl peptidase‐4 (DPP‐4) inhibitors or sodium‐glucose co‐transporter 2 (SGLT‐2) inhibitors) on time to insulin initiation among patients with type 2 diabetes.
Ya‐Hui Yu, Qi Zhang, Estefania Zapata‐Bravo, Robert W. Platt, Pauline Reynier, Oriana H. Y. Yu, Kristian B. Filion   +6 more
wiley   +1 more source

Diagnostic performance of SD‐ΔRR during physical stressors for identifying diabetic sensorimotor polyneuropathy

Journal of Diabetes Investigation, Volume 17, Issue 10, Page 1770-1781, October 2026.
Study population, methodology and key findings of the study. ABSTRACT Aims This study aimed to evaluate the clinical efficacy of SD‐ΔRR as a novel methodology for short‐duration heart rate variability (HRV) assessment for the diagnosis of diabetic sensorimotor polyneuropathy (DSPN) in patients with diabetes.
Katsuyoshi Katayama, Haruhito A. Uchida, Toshihiko Nagao, Jun Eguchi, Kenji Tsuji, Yoshinori Matsumoto, Ichiro Nojima, Keiko Tanaka, Hidemi Takeuchi, Yasuhiro Onishi, Rika Takemoto, Satoshi Miyamoto, Kenichi Shikata, Jun Wada   +13 more
wiley   +1 more source

Association of glycation gap with hypoglycemia CGM indices, diabetic complications, and quality of life in Japanese type 2 diabetes patients

Journal of Diabetes Investigation, Volume 17, Issue 10, Page 1794-1806, October 2026.
The difference between HbA1c and estimated A1c (eA1c) was defined as the GGap. The strong association of high GGap with CGM‐based hypoglycemic indices in type 2 diabetes is evident. The large GGap values, relying solely on HbA1c values during treatment, may increase the risk of hypoglycemia in patients with T2DM.
Satomi Sonoda, Yosuke Okada, Tomoya Mita, Keiichi Torimoto, Kenichi Tanaka, Fumiya Sato, Naoto Katakami, Hidenori Yoshii, Keiko Nishida, Shingo Nakayamada, Ryota Ishii, Masahiko Gosho, Iichiro Shimomura, Hirotaka Watada   +13 more
wiley   +1 more source